Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Super-cold container firm va-Q-tec expands to meet COVID-19 vaccine demand

11/24/2020 | 07:10am EDT
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Wuerzburg

FRANKFURT (Reuters) - Cold-storage specialist va-Q-tec is significantly expanding its fleet of 2,500 rental containers to meet growing demand to transport COVID-19 vaccines that need to be kept as low as -70 degrees Celsius (-94°F), its chief executive said.

The German company is in talks with all the major pharmaceutical manufacturers of COVID-19 vaccines, CEO Joachim Kuhn told Reuters in an interview.

Kuhn said the company would "significantly expand" its fleet of rental containers in the coming year. He did not specify how many extra containers were planned, though said it would not be to the extent of doubling the fleet.

Va-Q-tec is among a handful of high-end packaging providers who have found themselves in high demand as drugmakers and logistics firms prepares to transport such shots around the world. Its shares have risen by 230% this year, valuing the company at around $690 million.

The company's turnover has increased by 30% annually over the past 10 years. "We expect this growth to continue in a similar form," said the CEO, adding that global vaccine distribution might take several years.

"We are carefully increasing the number. With the market growing by more than 10% per year, we are not afraid that we will be left sitting on empty containers after corona."

The Würzburg-based company completed a 25 million Swiss franc ($27.4 million) bond issue on Monday to help fund its expansion plans.

It manufactures "passive" containers, which use dry ice to keep the contents at ultra-cold temperatures for up to five or six days, as opposed to "active" containers that also use electric motors for cooling.

The vaccine candidate developed by Pfizer and BioNTech, which uses mRNA technology, needs to be kept at about -70 degrees Celsius, colder than the offerings from Moderna Inc and AstraZeneca PLC.

Kuhn said va-Q-tec had contracts with the world's 20 largest airlines and major freight-forwarders. He said intercontinental transport with cargo flights was expected to be less of a problem than last-mile distribution on the road, given there was experience in transporting super-cold goods by air.

"To meet the demand for dry ice is not a big problem in our latitudes with sufficient regional production," Kuhn said. "It will be a challenge in countries that do not have this infrastructure in Africa, Latin America or Russia."

(Reporting by Ilona Wissenbach, Reuters TV; Writing by Jamie Freed; Editing by Pravin Char)

By Ilona Wissenbach


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.96% 8063 Delayed Quote.10.09%
VA-Q-TEC AG 0.32% 31.1 Delayed Quote.0.65%
All news about ASTRAZENECA PLC
09/17The case for, and against, COVID-19 vaccine boosters
RE
09/17ASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
PU
09/17ASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
BU
09/17AstraZeneca Sees Positive Results for Enhertu Trial
DJ
09/17ASTRAZENECA : EMA Fails To Find Link Between Blood Clots, AstraZeneca's Vaccine
MT
09/17ASTRAZENECA : Says Imfinzi-Oleclumab Combination Improved Clinical Outcomes for ..
MT
09/17JOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
AQ
09/17ASTRAZENECA : EU unsure if women face higher risk of clots from AstraZeneca shot
RE
09/17ASTRAZENECA : IMFINZI Combined With Novel Immunotherapies Improved Clinical Outc..
BU
09/17ASTRAZENECA : Buy rating from Morgan Stanley
MD
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,1x
Yield 2021 2,54%
Capitalization 172 B 172 B -
EV / Sales 2021 5,57x
EV / Sales 2022 4,50x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 110,77 $
Average target price 136,08 $
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.09%171 794
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456